What’s Hot: Bottling rays of sunshine
NEW YORK —Sales of the sunshine vitamin continue to heat up, especially as more clinical studies find that vitamin D is an essential nutrient that the body needs, and nobody’s getting enough of it. Not really.
“Vitamin D, that continues to be the ongoing superstar,” said Doug Jones, corporate communications and public relations manager at Pharmavite. According to Information Resources Inc., sales of vitamins A and D, which are tracked together, reached as high as $85.1 million in food, drug and mass (minus Walmart) on growth of 75.8% for the 52 weeks ended Sept. 6. And that growth continues to skyrocket—according to data provided by Pharmavite, sales of vitamin D alone are up 82% for the four weeks ended Sept. 9.
Researchers have noted that about half of adults, and more than half of children, are vitamin D deficient. Lifestyle factors, including increased sunscreen use and more time spent indoors, have contributed to these deficiencies.
Among the benefits of vitamin D, bone health possibly is the most well-known; vitamin D helps increase calcium absorption by as much as 65% as compared with calcium supplementation alone.
Hy-Vee celebrates the other white meat
WEST DES MOINES, Iowa A lot of people complain about pork barrel spending, but not Midwest supermarket chain Hy-Vee.
October is National Pork Month, and the West Des Moines, Iowa-based Hy-Vee announced Friday that sales of the meat have increased more than 25% over October 2008. The chain said it was on track to increase pork tonnage by more than 30%.
“With pork prices the lowest they’ve been in more than a decade, we’ve focused our marketing efforts on promoting pork as a great value for consumers,” Hy-Vee assistant VP meat operations Kenan Judge said in a statement. “Today’s shopper is looking for nutritious, economical meal ideas, and pork perfectly fits the bill.”
Patients prefer new diabetes drug Victoza over its competitor, survey finds
MONTREAL A new diabetes drug satisfied patients more than its competitor, according to a study funded by the drug’s manufacturer.
According to data on 379 patients who took the Diabetes Treatment Satisfaction Questionnaires, presented Thursday at the 20th World Diabetes Congress and published in medical journal The Lancet, patients taking Novo Nordisk’s drug Victoza (liraglutide) perceived less abnormally low or high blood sugar levels — known respectively as hypoglycemia and hyperglycemia — than those taking Byetta (exenatide), made by Eli Lilly & Co., Amylin Corp. and Alkermes.
Victoza is approved in Europe, but Novo Nordisk is still waiting for approval from the Food and Drug Administration in the United States.
“Liraglutide has shown here in a convincing study that it is associated with less nausea, less perceived hypoglycemia and definitely higher patient satisfaction compared to exenatide,” principal investigator Wolfgang Schmidt said in a statement. “Patient-reported outcomes data is an important extension of the efficacy data. If a patient is satisfied with his or her treatment, then they are much more likely to really stick to the treatment over the long term, which is necessary in Type 2 diabetes.”